Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor
23 Julio 2024 - 6:00AM
Frontier Medicines Corporation (“Frontier” or the “Company”), a
clinical-stage precision medicine company seeking to unlock the
proteome to advance transformational therapies against otherwise
undruggable disease-causing targets, today announced the
advancement of lead candidates for further optimization in an
AbbVie partnered program targeting a key transcription factor for
cancer cell survival, triggering an accompanying milestone payment.
“By applying the Frontier™ Platform, our team was able to target
a historically intractable transcription factor that has
implications across oncology treatment,” said Chris Varma, Ph.D.,
chairman, CEO, and co-founder of Frontier Medicines. “This progress
validates our platform’s ability to unlock undruggable targets for
small molecule treatment and we look forward to further advances in
our collaboration with AbbVie.”
Started in 2020, the objective of the global partnership is to
discover, develop, and commercialize a pipeline of innovative small
molecule therapeutics against certain high-interest,
difficult-to-drug protein targets.
About Frontier and AbbVie Partnership
Under the partnership, the companies will collaborate on the
research and pre-clinical development of programs directed to novel
E3 ligases, and certain immunology and oncology targets. AbbVie
will reimburse Frontier's R&D costs through defined stages of
pre-clinical development. Upon successful completion, AbbVie will
assume full responsibility for global development and
commercialization activities and costs for the programs. Frontier
will retain an option to share development activities and expenses
for certain oncology programs through the completion of Phase 2.
Frontier will be eligible to receive success-based development and
commercial milestone payments that could potentially exceed $1
billion, in addition to royalty payments on commercialized
products. AbbVie retains the right to expand the collaboration in
the future by exercising options to a defined number of additional
targets. The collaboration excludes all of Frontier's internal
programs for which Frontier retains exclusive global
rights.
About Frontier Medicines
Frontier Medicines is a clinical stage precision medicine
company pioneering groundbreaking medicines to transform treatment
for genetically-defined patient populations, starting with oncology
and immunology. Our proprietary chemoproteomics powered drug
discovery engine, the Frontier™ Platform, leverages covalent
chemistry and machine learning to unlock hard-to-treat disease
causing proteins for drug development. Today, we are advancing a
diversified pipeline of wholly-owned precision medicines against
the most important drivers of cancer and high-value immunology
programs. Our lead candidate, FMC-376, is a dual inhibitor of
ON+OFF KRASG12C. FMC-376 is a potential best-in-class therapy
designed to completely block both forms of the KRAS mutation to
overcome the lack of response and resistance seen with
single-acting KRASG12C inhibitors. For more information, please
visit www.frontiermeds.com. Follow Frontier on LinkedIn.
Frontier Medicines Contact:Victoria FortSVP,
Strategy and Corporate
AffairsVictoria.Fort@frontiermeds.com202.361.0445